George & Gem'S Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
as on 24-10-2024
- Paid Up Capital ₹ 0.10 M
as on 24-10-2024
- Company Age 13 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -46.69%
(FY 2023)
- Profit -0.91%
(FY 2023)
- Ebitda -71.14%
(FY 2023)
- Net Worth 70.05%
(FY 2023)
- Total Assets 51.64%
(FY 2023)
About George & Gem'S Pharmaceuticals
The Corporate was formerly known as Aryan Medipharma Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Usha Singh, Janmejay Singh, Vinay Singh, and One other member serve as directors at the Company.
- CIN/LLPIN
U51101UP2011PTC046665
- Company No.
046665
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Sep 2011
- Date of AGM
30 Nov 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Gorakhpur, Uttar Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at George & Gem'S Pharmaceuticals?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Usha Singh  | Director | 19-Sep-2011 | Current |
| Janmejay Singh | Director | 22-Jul-2023 | Current |
| Vinay Singh | Director | 22-Jul-2023 | Current |
| Anil Singh | Director | 22-Jul-2023 | Current |
Financial Performance of George & Gem'S Pharmaceuticals.
George & Gem'S Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 46.69% decrease. The company also saw a slight decrease in profitability, with a 0.91% decrease in profit. The company's net worth Soared by an impressive increase of 70.05%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of George & Gem'S Pharmaceuticals?
In 2023, George & Gem'S Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Aryan Human Care Private LimitedActive 14 years 3 months
Usha Singh and Janmejay Singh are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at George & Gem'S Pharmaceuticals?
Unlock and access historical data on people associated with George & Gem'S Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of George & Gem'S Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped George & Gem'S Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
